Seno Medical Instruments, Inc. (Seno Medical), a provider of new technology for breast cancer diagnosis using opto-acoustic ultrasound (OA/US) imaging to differentiate benign from malignant masses, has provided a summary of key 2018 data publications and presentations that demonstrate the clinical utility and healthcare economic benefits of its proprietary, cutting-edge technology.
"Multiple publications and presentations over the course of 2018 substantially strengthen the body of evidence emphasizing the economic costs of unnecessary breast biopsies and the power of our Imagio® Breast Imaging System to potentially reduce the number of these procedures," said Thomas Umbel, President and CEO of Seno Medical. "This growing evidence base further advances the compelling value proposition that Seno Medical offers to patients, physicians, and payers. We believe this robust body of evidence will help to position the Imagio system as a sound diagnostic tool for the breast imaging community. The selection of Imagio as a finalist for the 2018 Medtech Insight Awards in the 'Best Proof-of-Value of an Innovation' category demonstrates widespread recognition of our value proposition."
Previously unreported data publications and presentations include:
Previously reported data include:
Multiple publications, presentations underscore Seno Medical's value in reducing breast biopsies. Appl Rad Oncol.